2009 WHO
10 Strategic Advisory Group of Experts 2,3
SAGE 1
SAGE
2009
10
27~29
WHO 4
SAGE WHO
WHO TLAC
TLAC
the world's vaccines and immunization
2009
10
21
5
The State of
2010-2015 “ ” “ ”
“
”
“
”
SAGE SA 14-14-2 2011 SA 14-14-2 “ 2010 7 HIV RotaTeq 2009 4 1
HPV
”
1.2 2009 4 SAGE WHO
SAGE
Strategic Advisory Group of Experts (SAGE) terms of reference. Geneva, World Health Organization, 2008 (http://www.who.int/immunization/sage/SAGE_TORs_Full_21_11_08.pdf, 2009 11 ). 2 H1N1 2009 No. 49, 2009, pp. 305 308 3
http://www.who.int/immunization/sage/previous/en/index.html No 23, 2009, pp 220–237 5 State of the world’s vaccines and immunization, 3rd ed. Geneva, World Health Organization, UNICEF, The World Bank, 2009. ( http://www.who.int/immunization/documents/ISBN9789241563864/en/index.html.) 4
1
2009 5
4
23%~59% WHO UNICEF 6 6
2009
11
2
WHO
DTP3 WHO
82%
2010
2008 90%
3 72%
21
>80%
2009 Technical Advisory Group, TAG DTP3 37 HPV HIN1 “ H1N1
8 3
80% SAGE WHO
2009 ” Revolving Fund for Vaccine Procurement 2009 TAG TAG
TAG SIAs OPV HPV TAG TAG
6
Global action for prevention and control of pneumonia. Geneva, World Health Organization, UNICEF, 2009 (WHO/FCH/CAH/NCH/09.04). http://www.who.int/child_adolescent_health/documents/fch_cah_nch_09_04/en/index.html.
2
1
TAG 4 TAG
TAG
3
TAG
1
“ “ ”
” TAG
2010 2008 20 2 ≥95% 2008 92%
WHO
SAGE WHO
SIAs b HPV Hib)
3
2003 2012 SIAs 2000 82% 2009 13 18 SIAs 5 2008 1996~2002
2005 SIAs 92 2008 97% 2
SIAs
88% SAGE 1) 2012 MCV2
6 2012
SIAs 2) MCV2 2 3) 4) 5) 2 MCV2
GAVI GAVI ” AMC product profile, TPP) “ WHO UNICEF ” 2009 6 “ 7
“ UNICEF ” target
GAVI
“
10 ” Accelerated Vaccine Introduction PATH “ ” 5 GAVI 33 7
26 6
7
No. 1, 2008, pp. 1–16
4
GAVI GAVI 2011 DTP3 GAVI GAVI GAVI WHO SAGE SAGE HPV >70% A
Atlas
GAVI SAGE GAVI
SAGE IVAC WHO QUIVER TLAC 3
GACVS 2009 5 TLAC 10 3 3
2009 9
6
8
2009
SAGE WHO WHO
(ECBS)2009 2009 10
SAGE
SAGE
SAGE
Polio Eradication Initiative 2010 9
1 2015 2000
95%
<5/10
SAGE
8 9
No. 32, 2009, pp. 325–332 Global immunization vision and strategy 2006–2015. Geneva, World Health Organization, UNICEF. 2005 (WHO/IVB/05.05). ( http://www.who.int/immunization/documents/WHO_IVB_05.05/en/)
5
SAGE 2010 SAGE SAGE 10
1
SAGE OPV SAGE
“ 1 3 OPV1
”
(IPV)
“ NGOs IPV SAGE “ ”
SAGE ” OPV SAGE 11
OPV SAGE
SAGE 3 SAGE SAGE SAGE
2011 SAGE
“ 3~4 SAGE
” “go or no-go”
NGOs OPV SAGE IPV SAGE 10
WHO SAGE
“
” WHO OPV
Polio eradication evaluation. Geneva, Global Polio Eradication Initiative, 2009 (http://www.polioeradication.org/content/general/Polio_Evaluation_Report.asp, 11 No. 29, 2009, pp. 289–300
2009
11
)
6
SAGE
IPV
SAGE
WHO
SAGE
WHO
2001
O1 El Tor
O1/O139 “
B
”
SAGE “ 5 SAGE ” 3
7
SAGE a) b) (i) 5 3 (iii) (ii)
c)
HIV
d)
e) 2 SAGE
2
8
1 SAGE
2 SAGE
SAGE
WHO Shanchol
WHO GAVI 2013
Shantha Biotechnics Ltd., India Dukoral (SBL Vaccin, Sweden) Shanchol
NGOs SAGE
> 1
RTS,S/AS01 RTS, S/AS01 II III SAGE RTS,S/AS02 RTS,S/AS01 : RTS,S/AS01 50%[92% CI 32.9%~67.1%] RTS,S/AS02 32%(95% CI, 17.6%~47.6%) G IgG RTS,S/AS01 IgG GACVS RTS,S/AS01 8
5 ] III “
7 2010 6
11
III 12,000~16,000 [ (comorbidities)
2009 EPI 5~17
III ” Initiative for Vaccine Research–Global Malaria Programme Joint Technical Expert Group on Malaria Vaccines Entering Pivotal Phase III Trials and Beyond 2009 6 III
-
9
5
30
2010 SAGE SAGE intermittent preventive treatment in infants, IPTi intermittent preventive treatment in infants, IPTi 2009
IV
4
WHO IPTi 30%(95% CI, 19.8%~39.4%); <8 g/dl 21.3% (95% CI, 8.3%~32.5%); 23% (95% CI, 10.0%~34.0%) 6 EPI EPI IPTi IPTi IPTi 6
SAGE DTP 2 DTP2 SAGE WHO EPI UNICEF
DTP3 IPTi IPTi
EPI IPTi SAGE SAGE SAGE IPTi IPTi
IPTi /
10
SAGE (i) (ii) IPTi (iii) IPTi -
IPTi IPTi
IPTi
SAGE 2
2007
11 SAGE 1 “
” “
” IMMUNIZATIONbasics 1980 ”
“
SAGE WHO SAGE SAGE SAGE SAGE
SAGE
WHO 2400
SAGE SAGE GIVS 2010 80% 2000
SAGE
DTP3 2015
90%
11
“
”
SAGE
WHO SAGE GAVI SAGE ≤12
SAGE WHO Epidemiology Reference Group
“
Child Health ”
SAGE CDC SAGE SAGE
Sabin Vaccine Institute
6 “ ”
WHO SAGE
“
6
”
Weekly Epidemiological Record. No.50, 2009, pp.517-532